Collins Stewart initiates coverage on Isis Pharmaceuticals (Nasdaq: ISIS) with a Buy. Price target $17.

Collins analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE